FISH检测乳腺癌HER-2基因扩增及17号染色体多体状况及其临床病理学意义的分析

目的:总结分析临床应用荧光原位杂交(FISH)技术检测诊断乳腺癌大样本的经验和临床病理学意义。方法:用FISH技术诊断1 699例乳腺浸润性导管癌HER-2基因扩增和17号染色体多体状态,并分析HER-2基因扩增与其他重要生物指标及临床病理的关系。结果:乳腺癌HER-2基因扩增阳性率为52.6%(894/1 699);乳腺癌17号染色体多体阳性率为12.7%(216/1 699)。HER-2基因扩增与HER-2表达状况和17号染色体多体呈正相关,P值分别为0.000 1和0.009;乳腺癌HER-2基因扩增与肿瘤大小(P=0.008)、病理学分级(P=0.025)、淋巴结转移(P=0.015)和Ki-67(P=0.004)呈正相关,与ER(P=0.002)、PR(P=0.001)和Bcl-2(P=0.028)呈负相关。HER-2基因扩增的乳腺癌赫赛汀用药组预后明显优于未用药组(Log-rank=38.5;P=0.000 1);17号染色体多体的乳腺癌赫赛汀用药组患者较未用药组复发率低(P=0.022)。结论:临床应用FISH技术诊断HER-2基因扩增靶标来指导乳腺癌的分子靶向治疗可以明显改善患者的预后,值得进一步推广应用。

Clinicopathological application of fluorescence in situ hybridization technique to diagnose and analyse HER-2 gene amplification and chromosome 17 polysomy in invasive ductal breast cancer tissues

OBJECTIVE: To summarize and analyze the experience and clinicopathological significance in application of fluorescence in situ hybridization(FISH) technique to diagnose HER-2 gene amplification and chromosome 17 polysomy in large sample of invasive ductal breast cancer.METHODS: Status of HER-2 gene amplification and chromosome 17 polysomy was diagnosed by FISH technique and analyzed with other biomarkers and clincopathological data in 1 699 cases of invasive ductal breast cancer.RESULTS: The positive rate f...